About Voltage-gated potassium channel subunit beta-1
Voltage-gated potassium channel subunit beta-1 (KCNAB1) is a protein
from Homo sapiens identified by UniProt accession
Q14722, 419 residues long.
MolForge cross-references it against 0 known binders and
110 disease associations.
Target properties
| Protein name | Voltage-gated potassium channel subunit beta-1 |
| UniProt accession | Q14722 |
| Gene | KCNAB1 |
| Organism | Homo sapiens |
| Length | 419 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (110)
Diseases linked to this target (Open Targets).
- birth weight · score 0.41
- parental genotype effect measurement · score 0.37
- coronary artery disease · score 0.29
- Age-related nuclear cataract · score 0.20
- neurofibrillary tangles measurement · score 0.14
- gastric adenocarcinoma · score 0.10
- familial atrial fibrillation · score 0.07
- Brugada syndrome · score 0.07
- Romano-Ward syndrome · score 0.07
- Familial progressive cardiac conduction defect · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14722-F1 | alphafold | PREDICTED | 86.67 | — |
Amino-acid sequence (419 residues)
MLAARTGAAG SQISEENTKL RRQSGFSVAG KDKSPKKASE NAKDSSLSPS GESQLRARQL ALLREVEMNW YLKLCDLSSE HTTVCTTGMP HRNLGKSGLR VSCLGLGTWV TFGGQISDEV AERLMTIAYE SGVNLFDTAE VYAAGKAEVI LGSIIKKKGW RRSSLVITTK LYWGGKAETE RGLSRKHIIE GLKGSLQRLQ LEYVDVVFAN RPDSNTPMEE IVRAMTHVIN QGMAMYWGTS RWSAMEIMEA YSVARQFNMI PPVCEQAEYH LFQREKVEVQ LPELYHKIGV GAMTWSPLAC GIISGKYGNG VPESSRASLK CYQWLKERIV SEEGRKQQNK LKDLSPIAER LGCTLPQLAV AWCLRNEGVS SVLLGSSTPE QLIENLGAIQ VLPKMTSHVV NEIDNILRNK PYSKKDYRS
Explore Voltage-gated potassium channel subunit beta-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets